Lilly’s experimental drug cuts weight by 21% in diabetes trial - Regional Media News
The 12 mg dose cut body weight by 20.8% and lowered A1C by up to 1.6% in adults with type 2 diabetes and obesity, Lilly said.
- On Tuesday, Eli Lilly and Company announced TRIUMPH-2 Phase 3 trial results showing retatrutide helped adults with type 2 diabetes and obesity lose an average of 21% of body weight.
- As a first-in-class triple hormone receptor agonist, retatrutide targets GIP, GLP-1, and glucagon receptors; this mechanism differentiates it from existing treatments targeting only one or two hormones.
- The 80-week TRIUMPH-2 trial involved 1,152 participants across 92 sites; those receiving 12 mg achieved 20.8% average weight loss and significant A1C reductions, Lilly reported at the 62nd Annual Meeting.
- Cardiovascular risk factors improved significantly, with the highest dose delivering 58.3% reductions in high-sensitivity C-reactive protein. Common adverse events included nausea and diarrhea; discontinuation rates were 7.7% for the 12 mg dose.
- Eli Lilly plans to submit trial data to the FDA and other global health agencies early next year. Researchers suggest retatrutide could become a significant option for adults managing obesity alongside type 2 diabetes.
13 Articles
13 Articles
An experimental weight-loss drug has helped some severely obese people with type 2 diabetes lose about a quarter of their weight while keeping their blood sugar levels under control.
Lilly’s experimental drug cuts weight by 21% in diabetes trial - Regional Media News
Sept 29 (Reuters) - Eli Lilly said on Tuesday its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar) [...]
Watauga Democrat
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity
A new weight-loss drug, dubbed the "Godzilla" of pharmaceuticals, may not only help you lose up to a quarter of your body weight but also improve blood sugar levels and reduce inflammation. The latest results from international clinical trials indicate that Retatrutide could be a breakthrough in the treatment of obesity and type 2 diabetes, reports The Guardian.
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
